[go: up one dir, main page]

WO2008033326A3 - Method for determining treatment of individuals with fragile site - Google Patents

Method for determining treatment of individuals with fragile site Download PDF

Info

Publication number
WO2008033326A3
WO2008033326A3 PCT/US2007/019702 US2007019702W WO2008033326A3 WO 2008033326 A3 WO2008033326 A3 WO 2008033326A3 US 2007019702 W US2007019702 W US 2007019702W WO 2008033326 A3 WO2008033326 A3 WO 2008033326A3
Authority
WO
WIPO (PCT)
Prior art keywords
individuals
fragile site
determining treatment
determining
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/019702
Other languages
French (fr)
Other versions
WO2008033326A2 (en
Inventor
Lionel J Coignet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of WO2008033326A2 publication Critical patent/WO2008033326A2/en
Publication of WO2008033326A3 publication Critical patent/WO2008033326A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Provided are methods for determining a chemotherapy treatment for an individual diagnosed with or suspected of having cancer, a method for assisting in the development of a therapeutic plan for an individual and for determining whether a chemotherapeutic agent can induce breakage of a FRA12E fragile site.
PCT/US2007/019702 2006-09-11 2007-09-11 Method for determining treatment of individuals with fragile site Ceased WO2008033326A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84365706P 2006-09-11 2006-09-11
US60/843,657 2006-09-11

Publications (2)

Publication Number Publication Date
WO2008033326A2 WO2008033326A2 (en) 2008-03-20
WO2008033326A3 true WO2008033326A3 (en) 2008-12-11

Family

ID=39184288

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/019702 Ceased WO2008033326A2 (en) 2006-09-11 2007-09-11 Method for determining treatment of individuals with fragile site

Country Status (1)

Country Link
WO (1) WO2008033326A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005078136A1 (en) * 2004-02-06 2005-08-25 Health Research, Inc. Method of prognosis of metastasis by detection of fra12e fragile site within the smrt gene/locus at chromosome 12q24

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005078136A1 (en) * 2004-02-06 2005-08-25 Health Research, Inc. Method of prognosis of metastasis by detection of fra12e fragile site within the smrt gene/locus at chromosome 12q24

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOUDE C. ET AL.: "The Presence of the FRA12E/SMRT Fragile Site in the Genome of Prostate Cancer (CaP) Patients is a Predictor of Metastatic Development", FIRST AACR INTERNATIONAL CONFERENCE ON MOLECULAR DIAGNOSTICS IN CANCER THERAPEUTIC DEVELOPMENT, September 2006 (2006-09-01), pages ABSTR. NO. A60 *

Also Published As

Publication number Publication date
WO2008033326A2 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
WO2008039944A3 (en) Method and apparatus for providing analyte sensor insertion
WO2006107848A3 (en) Apparatus and methods for detecting position and migration of neurostimulation leads
WO2008002672A3 (en) Targets for use in diagnosis, prognosis and therapy of cancer
IL180997A0 (en) Diagnostic methods and kits utilizing platelet biomarkers for cancer
WO2008140774A3 (en) Methods for diagnosing and treating prostate and lung cancer
NO20090028L (en) Procedures and systems for determining penetration into reservoir zones
NO20082960L (en) Ligands with binding specificity for VEGF and / or EGFR and methods for their use
WO2008088579A3 (en) Microvascular obstruction detection and therapy
IL191538A0 (en) Method for diagnosing, prognosing and treating glioma
IS8770A (en) Patches, systems and methods for non-invasive glucose measurement
EP1755754A4 (en) System and method for wagering based on financial market indicators
EP2527466A3 (en) Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2006047787A3 (en) Method for monitoring disease progression or recurrence
WO2008067291A3 (en) Method and apparatus for managing glucose control
EP2074422A4 (en) Methods and kits for detecting prostate cancer biomarkers
EP2099083A4 (en) THIN-FILM LAMINATED BODY, MINE-LAYER MAGNETIC SENSOR USING THE THIN-FILM LAMINATED BODY, AND METHOD FOR MANUFACTURING THE THIN-FILM LAMINATED BODY
WO2008027218A3 (en) Drug electrotransport with hydration measurement of hydratable reservoir
PL2073864T5 (en) Blood recuperation device and method
SG121040A1 (en) Method and system for detecting leak in electronicdevices
WO2008011519A3 (en) Amigo-2 inhibitors for treating, diagnosing or detecting cancer
WO2009036427A3 (en) Prostate cancer biomarkers
WO2008131361A3 (en) Biosensors for measuring analytes in the interstitial fluid
IL185668A0 (en) Novel anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor
WO2007103146A3 (en) Truncated proteins as cancer markers
WO2006086442A3 (en) Method of detecting abnormal tissue

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07838006

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07838006

Country of ref document: EP

Kind code of ref document: A2